DisclaimerThis communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients' securities. See www.pcgadvisory.com/disclosures. Under the leadership of CE ...

Oncocyte Appoints Andrea James as Chief Financial Officer "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. "We expect 2024 and 2025 ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (NASDAQ:OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including thera ...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine. The trial evaluated the test's effectiveness in monitoring graft health in patients with antibody-mediated rejection (AMR), a leading cause of kidney transplant failure. The study's positive outcomes highlight new clinical uses for VitaGraft Kidney, including ther ...

Core Insights - Oncocyte Corporation announced favorable data for its product VitaGraft™ Kidney, published in the New England Journal of Medicine, indicating its potential in monitoring graft injury and therapeutic efficacy in kidney transplant patients [1][2] - The study demonstrated that VitaGraft Kidney can identify responders to the investigational drug felzartamab, showing significant reductions in donor-derived cell-free DNA (dd-cfDNA) at weeks 12 and 24 [2][3] - The results suggest new clinical applications for VitaGraft Kidney, including monitoring therapeutic efficacy and recurrence of antibody-mediated rejection (AMR) [2][3] Company Overview - Oncocyte is a precision diagnostics company focused on providing clarity and confidence to physicians and patients through its diagnostic tests [6] - The company’s products include VitaGraft™ for solid organ transplantation monitoring and GraftAssure™, a research-use-only test [6] - Oncocyte's technology aims to improve care and outcomes for high-risk kidney transplant patients suffering from AMR [4] Clinical Study Insights - The phase 2 trial indicated that monitoring dd-cfDNA could effectively detect responsiveness to felzartamab therapy and uncover disease recurrence after treatment cessation [3] - Up to 20.2% of kidney transplant patients may develop AMR within 10 years, with a significant percentage progressing to graft failure [3][7] - There are currently no FDA-approved drugs for managing AMR, highlighting a critical unmet need in transplant management [3] Future Prospects - Oncocyte's CEO expressed optimism about the study's potential to lead to new treatment options for kidney transplant patients globally [4] - The partnership with Bio-Rad is expected to enhance the scale and adoption of dd-cfDNA monitoring tools in the transplant research community [4] - The results will be presented at the 2024 American Transplant Congress, indicating ongoing engagement with the medical community [4][5]

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte's Drs. Ekke Schuetz and Julia Bec ...

Recent Highlights "In the first quarter of 2024, Oncocyte made significant progress toward commercializing its innovative blood-based diagnostic tests. That progress was bolstered by a $15.8 million equity private placement and a global strategic partnership with Bio-Rad Laboratories," said Josh Riggs, Oncocyte's CEO. "We believe that the collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction (I.R.S. ...

IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties may access the live call via telephone by dialing toll free (800) 715-9871 for bo ...

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an insightful interview with Oncocyte Corporation's Chief Executive Officer, Josh Riggs, as the company works to disrupt the mature diagnostics marketplace with a nimble, capital-light approach to growth. Oncocyte (NASDAQ:OCX) has developed and is preparing to commercialize precision tests in the transplant and oncology markets. The Company's transplant diagnostic tests, VitaGraft™ and GraftAssure™, measure the health of a ...